Document is current

Any future updates will be listed below

ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer—The Randomized Multicenter Phase II NEPAFOX Trial

Crossref DOI link: https://doi.org/10.1245/s10434-024-15145-8

Published Online: 2024-04-04

Published Print: 2024-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark